Researchers evaluated the frequency and severity of pain and fatigue in patients with psoriatic arthritis receiving tumor necrosis factor inhibitors.
The FDA has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Researchers assessed the effect of clinical enthesitis in patients with psoriatic arthritis.
Researchers assessed the reliability of a novel score to identify the characteristic lesions of dactylitis in psoriatic arthritis.
Researchers evaluated the use of acute mental health services after a diagnosis of rheumatoid arthritis or ankylosing spondylitis.
Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
The FDA has approved Cosentyx® for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
The FDA has approved Taltz for the treatment of active nonradiographic axial spondyloarthritis in patients with objective signs of inflammation.
Researchers assessed the effectiveness of steroid injections vs systemic treatment on dactylitis in patients with psoriatic arthritis.